Inactive Instrument

Highlights ProMIS Neurosciences, Inc. Toronto S.E.

Equities

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS	Apr. 09	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
ProMIS Neurosciences Announces Publication on Novel Target for ALS	Dec. 20	CI
Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease	Nov. 20	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF)	22-04-18	PR

No results for this search